II - Myocardial dysfunction - Heart failure
Cardiovascular collapse - Cardiogenic shock - Hypotension
Last update 17/06/2026
See also under Xf and XIIe, , f, g, k, l, o, s, t, ad, ag
II - Myocardial dysfunction - Heart failure
Last update 17/06/2026
See also under Xf and XIIe, , f, g, k, l, o, s, t, ad, ag
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.f Anaphylaxis - Anaphylactoid reaction (either of these can be fatal)
XXXVIII. Miscellaneous - Varia
XXXVIII.m Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea
XXXIX. Rechallenge
XXXIX.a Rechallenge can lead to near-fatal or fatal relapse of AE/ILD
XXXIX. Rechallenge
XXXIX.b Rechallenge can lead to relapse of AE/ILD
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
XV. Chest pain
XV.a Chest pain (acute or subacute), lone or prominent
XXVIII. Large airway involvement
XXVIII.a Angioedema (may cause UAO, asphyxia and death)
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
III. Myocardial ischemia - Coronary artery disease
III.c Coronary vasospasm - Vasospastic angina
VI. Cardiomyopathy
VI.a Cardiomyopathy (acute, subacute, chronic)
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
XI. Pulmonary vasculopathies
XI.a Pulmonary arterial hypertension
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.e Alveolar hemorrhage (AH), diffuse AH (DAH)
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.d Acute eosinophilic pneumonia (AEP)
XXVIII. Large airway involvement
XXVIII.a Angioedema (may cause UAO, asphyxia and death)
XXXVIII. Miscellaneous - Varia
XXXVIII.d Death following exposure or poisoning
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
XIII. Thrombosis - Embolism
XIII.a Pulmonary embolism - Venous thrombosis/thrombo-embolism
XIII. Thrombosis - Embolism
XIII.b Pulmonary vascular microthrombi
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS
XXIX. Small airway involvement
XXIX.a Bronchospasm - Wheezing - Asthma
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
III. Myocardial ischemia - Coronary artery disease
III.c Coronary vasospasm - Vasospastic angina
IV. Heart block (bundle branch-, AV-block)
IV.a Heart block (bundle branch- or AV-)
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
XIV. Pleural involvement
XIV.e Hemothorax - Serosanguineous pleural effusion
XV. Chest pain
XV.a Chest pain (acute or subacute), lone or prominent
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.e Alveolar hemorrhage (AH), diffuse AH (DAH)
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.h Coagulopathy
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.i Hemoptysis
XX. Vasculitis
XX.c Vascultis (pulmonary, extrathoracic or systemic) - ANCA status unknown or negative
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.f Diffuse alveolar damage (DAD) imaging pattern
XXVIII. Large airway involvement
XXVIII.a Angioedema (may cause UAO, asphyxia and death)
XXIX. Small airway involvement
XXIX.a Bronchospasm - Wheezing - Asthma
XXIX. Small airway involvement
XXIX.c Severe or catastrophic bronchospasm or asthma attack (can be fatal)
XXXIII. Histopathology (for pulmonary pathology see in ‘Pneumotox’ (a free companion App)
XXXIII.j Path: Pulmonary edema
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.f Anaphylaxis - Anaphylactoid reaction (either of these can be fatal)
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.l Cardiac- cardiorespiratory/pulmonary arrest
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
III. Myocardial ischemia - Coronary artery disease
III.c Coronary vasospasm - Vasospastic angina
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
XI. Pulmonary vasculopathies
XI.f Worsening of preexisting PHTn
XII. Pericardial involvement
XII.g Pleural/pericardial effusion, ANA positive (DI lupus)
XIV. Pleural involvement
XIV.a Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)
XIV. Pleural involvement
XIV.h Pleural thickening - Fibrothorax
XXII. Acute respiratory/cardiorespiratory failure
XXII.e Respiratory failure from ventilatory depression (of neuromuscular cause or causes)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.a Pneumonitis (ILD)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.e Relapsing or migrating pneumonitis/pneumonia (see also Id)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.h Pulmonary fibrosis (may improve but partly following drug discontinuation)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.j Organizing pneumonia (OP/BOOP) pattern (an area or areas of consolidation on imaging)
XXIX. Small airway involvement
XXIX.a Bronchospasm - Wheezing - Asthma
XXIX. Small airway involvement
XXIX.c Severe or catastrophic bronchospasm or asthma attack (can be fatal)
XXIX. Small airway involvement
XXIX.h Exacerbation or deterioration of preexisting asthma
XXIX. Small airway involvement
XXIX.i Exacerbation or deterioration of preexisting COPD
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.b Lupus - Lupus syndrome
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.d Subclinical ANA positivity
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.l Refractoriness to epineprine in case of anaphylaxis
XXXVIII. Miscellaneous - Varia
XXXVIII.d Death following exposure or poisoning
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.a Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.f Tachycardia
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.g QTc prolongation
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.l Cardiac- cardiorespiratory/pulmonary arrest
II. Myocardial dysfunction - Heart failure
II.a Left ventricular dysfunction/failure
II. Myocardial dysfunction - Heart failure
II.c Heart failure (biventricular, congestive)
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
II. Myocardial dysfunction - Heart failure
II.e Acute respiratory or cardiopulmonary failure
III. Myocardial ischemia - Coronary artery disease
III.c Coronary vasospasm - Vasospastic angina
III. Myocardial ischemia - Coronary artery disease
III.g ST segment changes
VI. Cardiomyopathy
VI.a Cardiomyopathy (acute, subacute, chronic)
VII. Cardiotoxicity
VII.a ‘Cardiotoxicity’
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
X. Pulmonary edema
X.c Interstitial pulmonary edema
XII. Pericardial involvement
XII.b Pericardial effusion (w/wo tamponade)
XIII. Thrombosis - Embolism
XIII.a Pulmonary embolism - Venous thrombosis/thrombo-embolism
XIV. Pleural involvement
XIV.a Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.i Hemoptysis
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.k Pulmonary infiltrates
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.y Cytokine release syndrome
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.a Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
III. Myocardial ischemia - Coronary artery disease
III.a Coronary artery disease (acute) - Myocardial ischemia/infarction
X. Pulmonary edema
X.a Pulmonary edema, cardiogenic
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
XXXVIII. Miscellaneous - Varia
XXXVIII.d Death following exposure or poisoning
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.e Bradycardia
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.l Cardiac- cardiorespiratory/pulmonary arrest
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
III. Myocardial ischemia - Coronary artery disease
III.c Coronary vasospasm - Vasospastic angina
II. Myocardial dysfunction - Heart failure
II.a Left ventricular dysfunction/failure
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
X. Pulmonary edema
X.a Pulmonary edema, cardiogenic
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
X. Pulmonary edema
X.h Negative pressure pulmonary edema (NPPE)
X. Pulmonary edema
X.m Neurogenic pulmonary edema
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
III. Myocardial ischemia - Coronary artery disease
III.a Coronary artery disease (acute) - Myocardial ischemia/infarction
III. Myocardial ischemia - Coronary artery disease
III.c Coronary vasospasm - Vasospastic angina
XV. Chest pain
XV.a Chest pain (acute or subacute), lone or prominent
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.e Alveolar hemorrhage (AH), diffuse AH (DAH)
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.a Pneumonitis (ILD)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.f Diffuse alveolar damage (DAD) imaging pattern
XXVIII. Large airway involvement
XXVIII.a Angioedema (may cause UAO, asphyxia and death)
XXIX. Small airway involvement
XXIX.a Bronchospasm - Wheezing - Asthma
XXX. Imaging features
XXX.l Imaging: Ground-glass opacities / GGO shadowing
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.f Anaphylaxis - Anaphylactoid reaction (either of these can be fatal)
XXXVIII. Miscellaneous - Varia
XXXVIII.k Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
IV. Heart block (bundle branch-, AV-block)
IV.a Heart block (bundle branch- or AV-)
XV. Chest pain
XV.a Chest pain (acute or subacute), lone or prominent
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.a Pneumonitis (ILD)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.h Pulmonary fibrosis (may improve but partly following drug discontinuation)
XXVII. Dyspnea, lone
XXVII.a Dyspnea, unexplained otherwise
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
II. Myocardial dysfunction - Heart failure
II.f Myocardial stunning
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
X. Pulmonary edema
X.e Overload pulmonary edema (including posttransfusional (TACO))
X. Pulmonary edema
X.k Transfusion-related acute lung injury (TRALI) (May cause ARDS)
XI. Pulmonary vasculopathies
XI.b Acute pulmonary hypertension
XV. Chest pain
XV.a Chest pain (acute or subacute), lone or prominent
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.e Alveolar hemorrhage (AH), diffuse AH (DAH)
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.f Diffuse alveolar damage (DAD) imaging pattern
XXVIII. Large airway involvement
XXVIII.a Angioedema (may cause UAO, asphyxia and death)
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.f Anaphylaxis - Anaphylactoid reaction (either of these can be fatal)
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.a Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.e Bradycardia
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.f Tachycardia
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.j Asystole
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.l Cardiac- cardiorespiratory/pulmonary arrest
II. Myocardial dysfunction - Heart failure
II.d Cardiovascular collapse - Cardiogenic shock - Hypotension
IV. Heart block (bundle branch-, AV-block)
IV.a Heart block (bundle branch- or AV-)
V. Myocarditis
V.a Myocarditis (can be fulminate/fulminant)
V. Myocarditis
V.b Eosinophilic myocarditis
VI. Cardiomyopathy
VI.a Cardiomyopathy (acute, subacute, chronic)
VII. Cardiotoxicity
VII.a ‘Cardiotoxicity’
VII. Cardiotoxicity
VII.b Veterinary: Cardiotoxicity
XIV. Pleural involvement
XIV.a Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.e Alveolar hemorrhage (AH), diffuse AH (DAH)
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS